We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Belluscura Plc | LSE:BELL | London | Ordinary Share | GB00BD3B8Z11 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 10.25 | 49,657 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 9.50 | 11.00 | 10.25 | 10.25 | 10.25 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | USD 825k | USD -18.52M | USD -0.1100 | -0.93 | 17.26M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:55:22 | O | 4,657 | 10.65 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 03/12/2024 | 07:00 | UK RNS | Belluscura PLC New Wound Care Joint Venture |
| 22/11/2024 | 07:00 | UK RNS | Belluscura PLC New $4million Credit Facility |
| 12/11/2024 | 16:34 | UK RNS | Belluscura PLC Holding(s) in Company |
| 28/10/2024 | 07:00 | UK RNS | Belluscura PLC Trading Update |
| 26/9/2024 | 17:12 | ALNC |  EARNINGS: Zephyr Energy interim loss narrows; Eqtec expenses surge |
| 26/9/2024 | 06:00 | UK RNS | Belluscura PLC Half-year Report |
| 13/9/2024 | 12:37 | UK RNS | Belluscura PLC Holding(s) in Company |
| 12/9/2024 | 14:05 | UK RNS | Belluscura PLC Holding(s) in Company |
| 27/8/2024 | 13:17 | UK RNS | Belluscura PLC Result of General Meeting |
| 27/8/2024 | 06:00 | UK RNS | Belluscura PLC AGM Trading Statement |
Belluscura (BELL) Share Charts1 Year Belluscura Chart |
|
1 Month Belluscura Chart |
Intraday Belluscura Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 03/12/2024 | 07:25 | BELLUSCURA - Enrichment through oxygen concentrators | 679 |
| 06/9/2017 | 22:56 | BELL POTTINGERS..crooked establishment whores who made deals with UZBEK govt | - |
| 25/1/2011 | 10:25 | Bellwethers in the Dow | - |
| 14/11/2010 | 09:01 | Bellwethers - can provide an Edge for Investors | 3 |
| 30/10/2010 | 11:45 | The BELLwethers | 3 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:55:23 | 10.65 | 4,657 | 495.97 | O |
| 11:27:42 | 10.67 | 5,000 | 533.73 | O |
| 10:39:53 | 10.55 | 10,000 | 1,054.50 | O |
| 10:20:42 | 10.55 | 30,000 | 3,163.50 | O |
| Top Posts |
|---|
Posted at 03/12/2024 08:20 by Belluscura Daily Update Belluscura Plc is listed in the Surgical,med Instr,apparatus sector of the London Stock Exchange with ticker BELL. The last closing price for Belluscura was 10.25p.Belluscura currently has 168,408,232 shares in issue. The market capitalisation of Belluscura is £17,261,844. Belluscura has a price to earnings ratio (PE ratio) of -0.93. This morning BELL shares opened at 10.25p |
Posted at 24/1/2024 08:18 by maytrees Good morningPossibly BELL share price has been held down recently by TEK selling 3.5m to fund raise? |
Posted at 25/10/2023 18:12 by hedgehog 100 Dr. Biotech,If TMTA didn't think that BELL was a good investment, then why would they (in effect) be investing here? Obviously with the BELL share price falling this month, the deal with TMTA has been changed to reflect that. It just goes to show that 'cash is king', especially at the moment. TMTA has it, & BELL wants it, which puts TMTA in the stronger bargaining position. Remember that the deal has to be approved by TMTA shareholders, and with the TMTA share price (at just 17p) trading at less than its cash per share, it's understandable that they would look for 'better' terms. And a wider issue is: what is the outlook for future new issues in the nearer term? Judging from TMTA's choice of BELL, there is nothing better in the offing at present (that has't already been accounted for by another shell, at least) ... The backdrop is that UK penny shares as a whole are depressed at the moment ... but that can change very quickly (especially for already listed shares). Interest rates won't stay this high for ever, so I think that now is the time to be picking up bargains, to ride the likely recovery. If you look back to late 2009, during the credit crunch, some of the bargains then now look absolutely mouth-watering. Which was reflected in the huge, multibagging gains which they subsequently recorded, some of which were pretty quick, relatively speaking. Now is, I believe, such as time. And as such, now is the time to, in effect, 'get rich'. |
Posted at 25/10/2023 10:45 by hedgehog 100 Date Time Source Headline Symbol Company25/10/2023 07:00 UK Regulatory (RNS & others) Belluscura PLC Statement regarding possible offer LSE:BELL Belluscura Plc "Statement regarding possible offer for TMT Acquisition plc The boards of Belluscura plc (AIM: BELL) and TMT Acquisition plc ("TMT Acquisition") announced on 3 October 2023 that they had reached agreement on the key terms of a possible share for share offer for TMT Acquisition by Belluscura (the "Possible Offer"). Both companies have completed confirmatory due diligence and expect to be in a position to announce a firm offer shortly, and by not later than 5.00 p.m. on 31 October 2023. The terms of the Possible Offer have been revised and will now comprise the issuance of 3 new ordinary shares of Belluscura ("Belluscura Shares") in exchange for every 4 ordinary shares of TMT Acquisition ("TMT Acquisition Shares") equaling 20,625,000 Belluscura Shares (the "Revised Exchange Ratio"). The Revised Exchange Ratio would imply a valuation of 20.25 pence for each TMT Acquisition Share based upon the Belluscura closing middle market price of 27.0p on 24 October 2023, being the last practicable date prior to the announcement of the Revised Possible Offer (the "Revised Possible Offer Terms"). Accordingly, on the basis of the Revised Exchange Ratio, the Revised Possible Offer Terms will imply a total valuation of GBP5.57 million for TMT Acquisition, representing a premium of approximately: -- 19.12 % to the closing price of a TMT Acquisition Share of 17.0p on 24 October 2023, being the last business day before this announcement; and -- 14.30 % to the TMT Acquisition three-month volume weighted average price for the period ending 24 October 2023, being the last business day before this announcement. The independent director of TMT Acquisition, Paul Tuson (the "Independent TMT Acquisition Director"), has reconfirmed to Belluscura that, should a firm offer be made on the Revised Possible Offer Terms (as outlined above), the Independent TMT Acquisition Director is minded to recommend it to TMT Acquisition shareholders. Any announcement by Belluscura of a firm intention to make an offer for TMT Acquisition remains subject to the satisfaction or waiver (by Belluscura) of a number of customary pre-conditions, including, inter alia, completion of confirmatory due diligence, agreement of the detailed terms of the Possible Offer and a recommendation from the Independent TMT Acquisition Director. ..." So, improved terms for TMTA, to reflect the dip in the BELL share price - these were probably necessary to get the deal approved by TMTA. Previously, the provisional arrangement was 15 BELL shares for every 22 TMTA shares; now the intended arrangement will equate to 16.5 BELL shares for every 22 TMTA shares: i.e. TMTA shareholders should get 10% more than previously. The current BELL share price is 26.5p (25p - 28p): which based on 3 BELL shares for every 4 TMTA shares equates to 19.875p (18.75p - 21p) TMTA. But TMTA is currently 17p (16p - 18p), giving a reasonably attractive arbitrage opportunity here again, especially if you can get inside the headline spreads. |
Posted at 07/10/2023 09:52 by hedgehog 100 These are what look to be three BELL-TMTA arbitrage trades on Thursday:-Belluscura (BELL) Date Time Trade Prc Volume Buy/Sell Bid Ask Value 05-Oct-23 12:31:16 32.7501 7,500 Sell* 32.00 38.00 2,456 O 05-Oct-23 10:39:32 32.722 7,377 Sell* 32.00 38.00 2,414 O 05-Oct-23 10:38:50 33.00 30,000 Sell* 32.00 38.00 9,900 O TMT Acquisition (TMTA) Date Time Trade Prc Volume Buy/Sell Bid Ask Value 05-Oct-23 12:31:55 20.40 12,000 Buy* 19.00 21.00 2,448 O 05-Oct-23 10:40:31 19.80 50,198 Unknown* 19.00 20.00 9,939 O 05-Oct-23 10:41:02 19.80 11,464 Buy* 19.00 20.00 2,270 O The seller of the 30,000 BELL trade looks to have bought 50,198 TMTA with the proceeds. On the basis that TMTA shareholders will receive 15 BELL shares for every 22 TMTA shares, this trader should receive 34,225 BELL shares for these 50,198 TMTA shares. I.e. a likely free 4,225 BELL shares: worth £1,394 at the current BELL mid price of 33p. And if Jonathan Satchell 40-bags BELL, as he did with Learning Technologies Group (LTG), 4,225 BELL shares could be worth over £50K. Which wouldn't be a bad return for what looks to have been an essentially risk-free arbitrage trade! The BELL-TMTA arbitrage benefit has now narrowed, but the window of opportunity is still open. Logically though you would expect it to narrow further and close, due to further arbitrage trading, & investors buying TMTA as a likely discounted route into BELL. |
Posted at 04/10/2023 15:40 by hedgehog 100 Closing s.p.s today:-BELL 35p (32p - 38p). TMTA 19.5p (19p - 20p). On the basis that TMTA shareholders will receive 15 BELL shares for every 22 TMTA shares, the current TMTA offer price of 20p/share equates to a BELL offer price of 29.33p/share, i.e. 22.82% less than the current BELL offer price of 38p. So TMTA is potentially a significantly cheaper way into BELL at the moment than buying BELL shares directly. Stuffee, Why don't you feel that TMTA shareholders will be natural shareholders for BELL? The whole point of buying a shell like TMTA is that it's potentially a cheaper route into a non-shell company; shell investors neither expect nor want it to remain a shell forever. And TMTA was set up specifically to invest into a tech company like BELL:- "TMT Acquisition was incorporated in March 2021. The Company has been formed to pursue opportunities to acquire businesses in the technology, media and telecom sector (“TMT sector”)." |
Posted at 30/8/2023 08:13 by buywell3 Ref the financial impact of this RNS --- buywell opines:Under the terms of the ten-year Agreement, effective from 1 October 2023, Belluscura is to receive annually increasing minimum cumulative royalties over the term of the Agreement. In addition to receiving royalties on licensed products (subject to annually increasing minimum amounts), Belluscura will receive a share of the net profits on sales of accessories. The Agreement will be exclusive for a minimum of 5 years, though if minimum sales quantities are not achieved, Belluscura and InnoMax can mutually agree to grant InnoMax a non-exclusive license for the remainder of the term. Minimum cumulative royalties over the term of the Agreement will therefore range from $27.5m if the license is converted to non-exclusive from year 6 and up to $55m in cumulative royalties if the license remains exclusive for the entire term. -------------------- buywell adds_ There are just shy of 135.67 Million Belluscura shares in issue according to FT $27.5 Million and $55 Million as stated in the RNS equate to 16p or 32p a BELL share On top of this BELL already have a US order for 6,500 in the bag Today's announcement follows news earlier this month that Belluscura has received purchase orders for over 6,500 of its DISCOV-R portable device for the US market, which the Company plans a controlled roll out of in Q3 and into 2024 to meet growing demand for the device amid substantial interest from medical device distributors, retailers, patients and durable medical equipment providers, among others. buywell adds That US order alone should equate to around $12M to 13M of revenue and looks set to rise in America due to increasing interest in the Belluscura products which have the NOMAD App -------------------- China is a much BIGGER market than the US for oxygen concentrators From the RNS Bob Rauker, Chief Executive Officer, Belluscura plc, commented: "I am very excited to build and strengthen our relationship with InnoMax. An estimated 100 million people suffer from COPD in China alone, approximately six times the number of patients in the US, demonstrating the need for oxygen therapy in China and associated Territories. This agreement provides the basis for an extremely financially beneficial partnership for both companies as we jointly broaden the reach of Belluscura's next-generation technology." -------------------- All of the above is to date , looking at the COPD market for the Belluscura products As yet the Long Covid and Sleep Apnea markets (using a Belluscura product as a CPAP) have not IMO been factored in IMO these additional markets combined could be larger than the COPD market as the lung/heart/organ damage and effects of Long Covid are further realized -------------------- Soon there will be approval news from the EU for Belluscura devices Existing BIG named EU Health Service providers of oxygen concentrators are currently talking to Belluscura to distribute their products More news on that also coming soon dyor imo Tekcapital (TEK) owns 15,138,767 shares of Belluscura plc (BELL) 11.16% |
Posted at 17/8/2023 07:13 by buywell3 17 August 2023Portfolio Companies Update Tekcapital Plc (AIM: TEK), the UK intellectual property investment group is pleased to provide a summary of latest developments across certain of its portfolio companies. Belluscura Belluscura plc ("Belluscura" AIM: BELL), announced on 16 August 2023 it has received purchase orders for over 6,500 of its next-generation DISCOV-R portable oxygen concentrator. This represents approximately US$15 million of potential revenue to Belluscura plc, as estimated by its management team. The recent purchase orders follow the signing of several distribution agreements with medical device distributors and other home healthcare providers, including a distribution agreement with a division of McKesson, one of the largest distributors of pharmaceuticals and medical devices in North America, earlier this month and a marketing agreement with GoodRx®, a leading digital healthcare platform, in February 2023. Belluscura has received multiple additional requests from leading oxygen homecare providers in the US to distribute the DISCOV-R. Tekcapital owns 15,138,767 shares of Belluscura plc (11.16%). -------------------- buywell notes that Tekcapital still is a Major Shareholder in Belluscura , holding 15,138,767 shares of Belluscura plc (11.16%). buywell hopes that Tekcapital can keep theses shares in Belluscura as they stage a recovery in share price based upon the coming surge of sales referred to in yesterdays Belluscura RNS and enhanced Telehealth software in the form of NOMAD its patented App , providing the necessary data for monitoring and control purposes by the remotely located patient Healthcare provider The news imo underpinned what the Belluscura CFO recently said in video ie: " Belluscura should be cash positive in the first half of 2024 " The chart of TEK IMO has been driven by that of BELL ---- hence buywell hopes and believes a recovery in the Belluscura share price chart --- which we are now seeing start to happen after the cash raise at 25p , could now drag the TEK share price chart back north. Note the current divergence caused by the surge in Belluscura SP plus As Belluscura starts to win market share from other existing oxygen concentrator providers , and sales into China and APAC begin in 2024 Belluscura with their disruptive patented technology will become a thorn in bigger sides Sooner rather than later one of them will want to remove that thorn dyor |
Posted at 08/4/2022 10:30 by maytrees Presumably TEK share price will show some gain too if this BELL share price gain continues. |
Posted at 16/3/2022 11:28 by maytrees Good morningDecent share price gain for BELL so far today though maybe simply because BELL share price recent fall was overdone. |
Posted at 13/1/2022 08:32 by maytrees Anyway the BELL share price is up again (so far) and earlier than usual today. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
